Loading news...
DaVita HealthCare (DVA) reached $111.01 at the closing of the latest trading day, reflecting a -3.23% change compared to its last close.
DaVita Inc. (NYSE: DVA - Get Free Report) reached a new 52-week low during trading on Tuesday after Truist Financial lowered their price target on the stock from $140.00 to $128.00. Truist Financial currently has a hold rating on the stock. DaVita traded as low as $111.43 and last traded at $113.19, with a volume of
Abacus FCF Advisors LLC trimmed its stake in DaVita Inc. (NYSE: DVA) by 60.3% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,677 shares of the company's stock after selling 23,857 shares during the period. Abacus FCF Advisors
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $116.51, denoting a +1.14% move from the preceding trading day.
Board of the Pension Protection Fund purchased a new position in shares of DaVita Inc. (NYSE: DVA) during the undefined quarter, according to its most recent 13F filing with the SEC. The firm purchased 6,400 shares of the company's stock, valued at approximately $850,000. Other hedge funds and other institutional investors have also
An aging population and rising AI adoption position the Zacks Medical - Outpatient and Home Healthcare industry for solid growth. EHC, DVA, OPCH and PNTG stand to benefit.
DVA stock gets support from a patient-centric model, Q3 revenue growth and overseas expansion, even as reliance on commercial payers remains a risk.
California Public Employees Retirement System decreased its position in shares of DaVita Inc. (NYSE: DVA) by 22.9% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 153,815 shares of the company's stock after selling 45,576 shares during the period.
Appointments of Chief People Officer and Chief Strategy Officer underscore commitment to innovation and people-first approach DENVER , Dec. 11, 2025 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced two key additions to its executive leadership team: Stephanie Hendrickson has been named Chief People Officer (CPO) and Steve Phillips will serve as Chief Strategy Officer (CSO), effective immediately. Both leaders bring more than a decade of proven success at DaVita and deep expertise that will help shape the company's next chapter of growth and innovation.
DaVita (DVA) is rated a speculative 'Buy,' reflecting undervaluation despite recent earnings volatility. DVA's moat stems from its dominant US dialysis clinic network, but its reliance on Medicare reimbursement and lack of dividend heighten risk. Trading below 11.5x P/E, DVA offers potential double-digit annual returns if it reverts to historical valuation multiples.
Edgestream Partners L.P. purchased a new stake in shares of DaVita Inc. (NYSE: DVA) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 44,754 shares of the company's stock, valued at approximately $6,375,000. Edgestream Partners L.P. owned approximately 0.06% of DaVita at
Hsbc Holdings PLC lowered its holdings in DaVita Inc. (NYSE: DVA) by 4.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 144,780 shares of the company's stock after selling 6,138 shares during the period. Hsbc Holdings PLC owned approximately 0.20% of
Boston Partners reduced its position in shares of DaVita Inc. (NYSE: DVA) by 13.3% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 79,074 shares of the company's stock after selling 12,151 shares during the period. Boston Partners owned 0.11%
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?
Fresenius SE and Co. (OTCMKTS:FSNUY - Get Free Report) and DaVita (NYSE: DVA - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings. Analyst Ratings This is a summary of
DaVita Inc. ( DVA ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 11:20 AM EST Company Participants Joel Ackerman - CFO & Treasurer Conference Call Participants Justin Lake - Wolfe Research, LLC Presentation Justin Lake Wolfe Research, LLC All right. Good morning.
DENVER , Nov. 14, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, will participate in a fireside chat at the Wolfe Research Healthcare Conference on Monday, November 17, 2025, at 11:20 am EST. To view the live webcast, visit the Wolfe Research page here and create a free registration.
Six new studies from DaVita Clinical Research spotlight improved outcomes with GLP-1 use, advancements in treatments, transplant access and end-of-life care DENVER and HOUSTON , Nov. 4, 2025 /PRNewswire/ -- DaVita, a steadfast leader in kidney care research and innovation, is unveiling six new studies at the American Society of Nephrology's (ASN) Kidney Week 2025, taking place Nov. 5-9 in Houston, Texas. These studies reflect DaVita's ongoing commitment to advancing kidney treatment through data-driven insights — spanning dialysis treatments, including emerging pathways to middle molecule clearance, and expanding access to transplantation, end-of-life care and more.
Y Intercept Hong Kong Ltd bought a new stake in DaVita Inc. (NYSE: DVA) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 8,725 shares of the company's stock, valued at approximately $1,243,000. Other institutional investors also recently added to or reduced their
Bessemer Group Inc. cut its position in shares of DaVita Inc. (NYSE: DVA) by 54.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,171 shares of the company's stock after selling 3,846 shares during the period. Bessemer Group Inc.'s